Ferucarbotran, a carboxydextran-coated superparamagnetic iron oxide nanoparticle, induces endosomal recycling, contributing to cellular and exosomal EGFR overexpression for cancer therapy

Abstract

In ferucarbotran-labeled hMSCs, the internalized EGFRs are mostly redirected from late endosomes/lysosomes to recycling endosomes, which protects the lysosomal degradation of EGFR and results in cellular (membranous) and exosomal EGFR overexpression.